Research progress of THR-β agonists in the treatment of MASH

分享到

Link by DOI

作者: Ma, Si-Min Zhu, Han-Xiao Li, Yu-Qing Long, Bao-Bang Kong, Rui Du, Cheng-Lin Li, Fu-Rong Zhi, Ying

作者单位: ^aSchool of Pharmaceutical Sciences and Institute of Materia Medica, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China

关键词: agonist metabolic dysfunction-associated fatty liver disease metabolic dysfunction-associated steatohepatitis thyroid hormone receptor β

摘要: Metabolic dysfunction-associated steatohepatitis has been identified as one of the leading factors contributing to the rising incidence of advanced liver disease, with its prevalence increasing annually. Currently, the primary treatment strategies focus on lifestyle modifications, including dietary adjustments and physical exercise, with weight loss being particularly crucial. Meanwhile, significant progress has been made in the development of pharmacological treatments, especially thyroid horm...更多; Metabolic dysfunction-associated steatohepatitis has been identified as one of the leading factors contributing to the rising incidence of advanced liver disease, with its prevalence increasing annually. Currently, the primary treatment strategies focus on lifestyle modifications, including dietary adjustments and physical exercise, with weight loss being particularly crucial. Meanwhile, significant progress has been made in the development of pharmacological treatments, especially thyroid hormone receptor β agonists, which have garnered considerable attention due to their potential efficacy in MASH treatment. This review aims to provide an in-depth exploration of the latest research advancements in THR-β agonists for MASH treatment, offering new therapeutic strategies and perspectives for clinical practice.收起

列表公用js 卡片页统计